Intersect ENT
Intersect ENT is a medical technology company based in Menlo Park, California, and a subsidiary of Medtronic. Founded in 2003 by Don Eaton with ENT surgeon Mary Lynn Moran, it develops drug-delivery devices for Ear, Nose & Throat conditions, especially sinusitis. Its best-known product is the PROPEL family—a bioabsorbable, drug-eluting stent that delivers mometasone furoate directly to the sinuses to reduce inflammation and keep passages open after surgery. The company also offers PROPEL Mini, PROPEL Contour, and Sinuva.
Intersect ENT holds more than 20 U.S. patents and over 80 patents and patent applications worldwide. It has earned industry recognition including Forbes’ America's Most Promising Companies list and Fierce 15 in 2013.
The company originally operated from Palo Alto and moved to a 32,000-square-foot facility in Menlo Park in 2012 to house its operations. Early venture backers included Medtronic and firms such as Kleiner Perkins, U.S. Venture Partners, PTV Sciences, and Norwest Venture Partners. A $30 million Series D in 2013, led by Norwest, supported commercial expansion of PROPEL products and the development of new drug-delivery devices. Intersect ENT went public on NASDAQ in 2014 (ticker XENT). By 2019 it employed about 400 people and generated around $115 million in revenue.
In August 2021, Medtronic announced it would acquire Intersect ENT for $1.1 billion, and the acquisition closed in May 2022. In addition to PROPEL, the RESOLVE device, launched in 2014, offers an in-office treatment for chronic sinusitis as an alternative to surgery and oral steroids.
This page was last edited on 2 February 2026, at 04:29 (CET).